Kantarjian H, Pui CH, Jabbour E. Acute lymphocytic leukaemia. Lancet. 2025;406:950–62.

Article  PubMed  Google Scholar 

Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Inaba H, Pui CH. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia. J Clin Med. 2021;10:1926.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Angiolillo AL, Schore RJ, Kairalla JA, Devidas M, Rabin KR, Zweidler-McKay P, et al. Excellent outcomes with reduced frequency of vincristine and dexamethasone pulses in standard-risk B-lymphoblastic leukemia: results from Children’s Oncology Group AALL0932. J Clin Oncol. 2021;39:1437–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pieters R, de Groot-Kruseman H, Fiocco M, Verwer F, Van Overveld M, Sonneveld E, et al. Improved outcome for ALL by prolonging therapy for IKZF1 deletion and decreasing therapy for other risk groups. J Clin Oncol. 2023;41:4130–42.

Article  CAS  PubMed  Google Scholar 

Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119:6226–33.

Article  CAS  PubMed  Google Scholar 

Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974–7.

Article  CAS  PubMed  Google Scholar 

Topp MS, Gökbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134–40.

Article  CAS  PubMed  Google Scholar 

Amgen Inc. BLINCYTO® (blinatumomab) for injection, for intravenous use. Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557s029lbl.pdf. Accessed on March 14, 2026.

Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493–8.

Article  CAS  PubMed  Google Scholar 

Topp MS, Gökbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120:5185–7.

Article  CAS  PubMed  Google Scholar 

Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57–66.

Article  CAS  PubMed  Google Scholar 

Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, et al. FDA approval: blinatumomab. Clin Cancer Res. 2015;21:4035–9.

Article  CAS  PubMed  Google Scholar 

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinelli G, Boissel N, Chevallier P, Ottmann O, Gökbuget N, Topp MS, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome–positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35:1795–802.

Article  CAS  PubMed  Google Scholar 

Litzow MR. Blitzing ALL with blinatumomab. Blood. 2025;145:2400–2.

Article  CAS  PubMed  Google Scholar 

Pulte ED, Vallejo J, Przepiorka D, Nie L, Farrell AT, Goldberg KB, et al. FDA supplemental approval: blinatumomab for treatment of relapsed and refractory precursor B-cell acute lymphoblastic leukemia. Oncologist. 2018;23:1366–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522–31.

Article  PubMed  PubMed Central  Google Scholar 

Jen EY, Xu Q, Schetter A, Przepiorka D, Shen YL, Roscoe D, et al. FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease. Clin Cancer Res. 2019;25:473–7.

Article  CAS  PubMed  Google Scholar 

von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34:4381–9.

Article  Google Scholar 

Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:833–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:843–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rabik CA, Wang S, Chadda R, Przepiorka D, Vallejo J, Jiang X, et al. FDA approval summary: Blinatumomab for the treatment of B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy. Clin Cancer Res. 2025;31:4230–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hogan LE, Brown PA, Ji L, Xu X, Devidas M, Bhatla T, et al. Children’s Oncology Group AALL1331: Phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-Cell ALL in first relapse. J Clin Oncol. 2023;41:4118–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376:2009–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barredo JC, Devidas M, Lauer SJ, Billett A, Marymont M, Pullen J, et al. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a Pediatric Oncology Group study. J Clin Oncol. 2006;24:3142–9.

Article  CAS  PubMed  Google Scholar 

Hastings C, Chen Y, Devidas M, Ritchey AK, Winick NJ, Carroll WL, et al. Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: a report from the Children’s Oncology Group study AALL02P2. Pediatr Blood Cancer. 2021;68:e29256.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lyons KU, Gore L. Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia. Haematologica. 2024;109:1668–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klinger M, Zugmaier G, Nagele V, Goebeler ME, Brandl C, Stelljes M, et al. Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events. Cancer Res. 2020;80:91–101.

Article  CAS